Role of Inflammatory Markers in Sepsis

National Cancer Institute, Egypt

Status: Enrolling

Conditions: Diagnostic

Treatments: Diagnostic Test: Serology tests

Study type: Observational

Funder types: Other

Identifiers

NCT06111963

AP2305-301-001

Details and patient eligibility

About

A diagnostic and prognostic study, in which the expression of CD64 in activated neutrophils and CD64 and IL17A regulatory T cells in patients with sepsis will be evaluated as a probable marker for sepsis as a primary objective

Enrollment: 60 estimated patients

Sex: All

Ages: 18 to 65 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Cancer patients admitted to the surgical ICU following cancer related surgeries and diagnosed with sepsis

Exclusion criteria

• Refusal of patient or patient guardian to participate.
• Intraoperative massive blood loss and massive blood transfusion
• Patients with impaired preoperative kidney or liver function tests

Trial design

60 participants in 2 patient groups

Septic patients

Treatment:

Diagnostic Test: Serology tests

Non Septic patients

Treatment:

Diagnostic Test: Serology tests